James Relf
About
James Relf is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology.
According to data from OpenAlex, James Relf has authored 34 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 28 papers in Pathology and Forensic Medicine and 9 papers in Immunology. Recurrent topics in James Relf's work include Lymphoma Diagnosis and Treatment (28 papers), CAR-T cell therapy research (28 papers) and Chronic Lymphocytic Leukemia Research (8 papers). James Relf is often cited by papers focused on Lymphoma Diagnosis and Treatment (28 papers), CAR-T cell therapy research (28 papers) and Chronic Lymphocytic Leukemia Research (8 papers). James Relf collaborates with scholars based in Switzerland, United Kingdom and Italy. James Relf's co-authors include Linda Lundberg, Carmelo Carlo‐Stella, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Martin Hutchings, Kathryn Humphrey, Nancy L. Bartlett, Fritz Offner and David Carlile and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Pharmacology & Therapeutics.
In The Last Decade
James Relf
30 papers receiving 282 citations
Peers
James Relf
Linda Lundberg Switzerland
Dena DeMarco United States
Keith Fay Australia
Cyrus Khan United States
Michelle Poon Singapore
Horst Hummel Germany
Yazeed Sawalha United States
Elizabeth Budde United States
Sandrine Montheard United States
Citations per year, relative to James Relf James Relf (= 1×)
peers
Linda Lundberg
Countries citing papers authored by James Relf
Since
Specialization
Citations
This map shows the geographic impact of James Relf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Relf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Relf more than expected).
Fields of papers citing papers by James Relf
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by James Relf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Relf. The network helps show where James Relf may publish in the future.
Co-authorship network of co-authors of James Relf
This figure shows the co-authorship network connecting the top 25 collaborators of James Relf. A scholar is included among the top collaborators of James Relf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Relf. James Relf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hutchings, Martin, Anna Sureda, Francesc Bosch, et al.. (2025). Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. Journal of Clinical Oncology. 43(36). 3788–3798.
2.
Jamois, Candice, David C. Turner, Leonid Gibiansky, et al.. (2025). Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL. Clinical Pharmacology & Therapeutics. 118(4). 917–927.
3.
Phillips, Tycel, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2024). Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.. Journal of Clinical Oncology. 42(16_suppl). 7008–7008.
4.
Phillips, Tycel, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2024). Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. Journal of Clinical Oncology. 43(3). 318–328.
5.
Phillips, Tycel, Marek Trněný, Carmelo Carlo‐Stella, et al.. (2024). Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study. Blood. 144(Supplement 1). 1631–1631.
6.
Falchi, Lorenzo, Martin Hutchings, Carmelo Carlo‐Stella, et al.. (2024). Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma. Haematologica. 110(4). 999–1004.
7.
Gregory, Gareth P., Jeremy S. Abramson, Huiqiang Huang, et al.. (2024). Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study. Blood. 144(Supplement 1). 5132–5132.
8.
Bartlett, Nancy L., Michael Dickinson, Martin Hutchings, et al.. (2024). Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study.. Journal of Clinical Oncology. 42(16_suppl). 7020–7020.
9.
Hutchings, Martin, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2024). ABCL-340 Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume. Clinical Lymphoma Myeloma & Leukemia. 24. S473–S473.
10.
Diefenbach, Catherine, Paolo F. Caimi, Nakhle S. Saba, et al.. (2024). Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study. Blood. 144(Supplement 1). 987–987.
11.
Carlo‐Stella, Carmelo, Martin Hutchings, Fritz Offner, et al.. (2023). GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATION. Hematological Oncology. 41(S2). 63–65.
12.
Falchi, Lorenzo, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2023). Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.. Journal of Clinical Oncology. 41(16_suppl). 7550–7550.
13.
Dickinson, Michael, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2023). GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY. Hematological Oncology. 41(S2). 144–146.
14.
Phillips, Tycel, Michael Dickinson, Franck Morschhauser, et al.. (2023). MCL-467 Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 23. S462–S462.
15.
Dickinson, Michael, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2022). Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.. Journal of Clinical Oncology. 40(16_suppl). 7500–7500.
16.
Dickinson, Michael, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2021). Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts). Blood. 138(Supplement 1). 2478–2478.
17.
Phillips, Tycel, Michael Dickinson, Franck Morschhauser, et al.. (2021). Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy. Blood. 138(Supplement 1). 130–130.
18.
Morschhauser, Franck, Carmelo Carlo‐Stella, Michael Dickinson, et al.. (2021). Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). Blood. 138(Supplement 1). 128–128.
19.
Carlo‐Stella, Carmelo, Cyrus Khan, Martin Hutchings, et al.. (2021). ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts). Clinical Lymphoma Myeloma & Leukemia. 21. S394–S394.
20.
Carlo‐Stella, Carmelo, Cyrus Khan, Martin Hutchings, et al.. (2021). Oral Abstract: ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts). Clinical Lymphoma Myeloma & Leukemia. 21. S203–S203.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Linda Lundberg Breakdown of academic impact, for papers by Dena DeMarco Breakdown of academic impact, for papers by Keith Fay Breakdown of academic impact, for papers by Cyrus Khan Breakdown of academic impact, for papers by María Dolores Caballero Barrigón Breakdown of academic impact, for papers by Michelle Poon Breakdown of academic impact, for papers by Horst Hummel Breakdown of academic impact, for papers by Yazeed Sawalha Breakdown of academic impact, for papers by Elizabeth Budde Breakdown of academic impact, for papers by Sandrine Montheard